Rallybio is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The company’s lead program is a plasma-derived polyclonal human antibody to human platelet antigen-1a (HPA-1a) for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). FNAIT is a devastating, rare disorder that is potentially life-threatening for unborn babies and newborns. RallyBio is led by highly experienced executives formerly from Alexion, a leading rare disease company, and is building a pipeline of additional assets against high unmet need rare diseases. Rallybio is headquartered in New Haven, Connecticut.